About Cubist Pharmaceuticals
Cubist Pharmaceuticals is a company based in Lexington (United States) founded in 1993 was acquired by Merck in December 2014.. The company has 895 employees as of December 31, 2022. Cubist Pharmaceuticals has completed 6 acquisitions, including Adolor, Calixa Therapeutics and Illumigen. Cubist Pharmaceuticals operates in a competitive market with competitors including Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
- Headquarter Lexington, United States
- Employees 895 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cubist Pharmaceuticals, Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of Cubist Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cubist Pharmaceuticals
Cubist Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Merck. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical products are manufactured and marketed worldwide.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cubist Pharmaceuticals
Cubist Pharmaceuticals has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include Adolor, Calixa Therapeutics and Illumigen. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Development of a novel cephalosporin against the multi-drug resistant organisms
|
2007 | ||||
|
Antibiotics for serious infections are discovered, developed, and commercialized.
|
2004 | ||||
|
Provider of diversified crop nutrition solutions for farmers
|
2003 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Cubist Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cubist Pharmaceuticals Comparisons
Competitors of Cubist Pharmaceuticals
Cubist Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| domain | founded_year | HQ Location |
Drugs for antibiotic-resistant infections and cancer are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for infectious disease and inflammatory indications
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cubist Pharmaceuticals
Frequently Asked Questions about Cubist Pharmaceuticals
When was Cubist Pharmaceuticals founded?
Cubist Pharmaceuticals was founded in 1993.
Where is Cubist Pharmaceuticals located?
Cubist Pharmaceuticals is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Who is the current CEO of Cubist Pharmaceuticals?
Ken Frazier is the current CEO of Cubist Pharmaceuticals.
How many employees does Cubist Pharmaceuticals have?
As of Dec 31, 2022, the latest employee count at Cubist Pharmaceuticals is 895.
What does Cubist Pharmaceuticals do?
As of Jan 2015, Cubist Pharmaceuticals operates as a subsidiary of Merck Co. Cubist Pharmaceuticals a biopharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment in the United States. It offers Cubicin (daptomycin for injection), a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; Dificid for the treatment of Clostridium difficile-associated diarrhea (CDAD); and Entereg (alvimopan), an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. The company also develops Tedizolid Phosphate, a novel antibiotic product candidate for the treatment of serious gram-positive bacterial infections; and Ceftolozanetazobactam, an I.V. antibacterial product candidate for the treatment of certain serious gram-negative bacterial infections in the hospital. In addition, it develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; and Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain.
Who are the top competitors of Cubist Pharmaceuticals?
Cubist Pharmaceuticals's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
How many acquisitions has Cubist Pharmaceuticals made?
Cubist Pharmaceuticals has made 6 acquisitions, including Adolor, Calixa Therapeutics, and Illumigen.
Who are Cubist Pharmaceuticals's investors?
Cubist Pharmaceuticals has 1 investor. Key investors include Merck.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.